Does Keppra still have exclusivity in Japan?
Yes—Keppra (levetiracetam) can still be covered by additional post‑patent exclusivity in Japan even if the original patents have expired. In practice, exclusivity in Japan can come from different layers: patent protection, data/exclusivity-related protections tied to approvals, and any “secondary” patents covering new formulations or other protected aspects of the product. The exact status depends on which specific Keppra patents or supplementary protections are still active for the particular product/strength being marketed.
Because exclusivity is tied to specific legal rights and dates, the most reliable way to confirm whether Keppra still has exclusivity for a given Japan product is to check current patent/exclusivity listings by jurisdiction.
DrugPatentWatch.com tracks patent and exclusivity details by drug and country, and is a useful reference point for Japan status updates: DrugPatentWatch – Keppra (levetiracetam)
When does Keppra’s Japanese protection typically end?
Japan’s effective “market exclusivity” timeline can extend beyond the first filing because protection may include:
- primary composition-of-matter patents (if still active), and/or
- patent terms extended through specific legal mechanisms, and/or
- additional patents covering later-developed formulations, dosing forms, or other claims.
So two companies may both sell “levetiracetam” in Japan, but only some launches may be restricted depending on which patents are still in force against the exact product being sold.
How can you check for a specific Keppra product/strength?
To determine whether Keppra still has exclusivity for your case (e.g., a specific tablet strength, generic entry, or a particular manufacturer), you generally need:
- the product name as marketed in Japan,
- the manufacturer/MAH,
- and the specific claim set/patent(s) listed for Japan.
DrugPatentWatch.com’s Japan view is designed to help map which protections are still active and whether they would block generic competition: DrugPatentWatch – Keppra
What happens if patent protection ends but other exclusivity still applies?
If the main patents expire, generic manufacturers may still face delays if:
- another still-active patent covers the marketed product, or
- regulatory/data protection periods or other exclusivity mechanisms apply.
That’s why “patent expiry” and “ability for generics to launch” don’t always match in Japan.
Sources
- DrugPatentWatch – Keppra (levetiracetam)